St. Luke's University Health Network, headquartered in Bethlehem, Pennsylvania, is a non-profit network of 12 hospitals and over 300 outpatient sites. The health network has over 16,000 employees.

There are 480 beds in St. Luke's University Health Network.

During the past decade, St. Luke's University Health Network conducted 63 clinical trials. In the 10-year time frame, 63 clinical trials started and 43 clinical trials were completed, i.e. on average, 68.3% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 25 clinical trials were completed. i.e. 125% of trials that started reached the finish line.

Out of the total clinical trials conducted in "St. Luke's University Health Network" #1 sponsor was "Bristol-Myers Squibb" with 10 trials, followed by "Hoffmann-La Roche" with 7 trials sponsored, "St. Luke's Hospital, Pennsylvania" with 6 trials sponsored, "Medtronic" with 4 trials sponsored and "Abbott Medical Devices" with 4 trials sponsored. Other sponsors include 71 different institutions and companies that sponsored additional 63 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "St. Luke's University Health Network" #1 collaborator was "National Cancer Institute (NCI)" with 7 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 5 trials as a collaborator, "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "Massachusetts General Hospital" with 3 trials as a collaborator and "Columbia University" with 2 trials as a collaborator. Other collaborators include 125 different institutions and companies that were collaborators in the rest 127 trials.

According to Clinical.Site data, the most researched conditions in "St. Luke's University Health Network" are "Melanoma" (11 trials), "Breast Cancer" (5 trials), "Heart Failure" (4 trials), "Metastatic Melanoma" (4 trials) and "Chronic Pain" (3 trials). Many other conditions were trialed in "St. Luke's University Health Network" in a lesser frequency.

Most popular intervention types in "St. Luke's University Health Network" are "Drug" (69 trials), "Device" (15 trials), "Biological" (11 trials), "Other" (10 trials) and "Procedure" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Atezolizumab" (5 trials), "Nivolumab" (5 trials), "Cobimetinib" (4 trials) and "Docetaxel" (4 trials). Other intervention names were less common.

The vast majority of trials in "St. Luke's University Health Network" are 96 trials for "All" genders, 9 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "St. Luke's University Health Network". undefined are not yet recruiting, 18 are recruiting, 15 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 57 completed trials in St. Luke's University Health Network, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in St. Luke's University Health Network, 8 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 42 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 11 trials that are defined as “Not Applicable".